- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01151540
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
November 15, 2018 updated by: Eisai Co., Ltd.
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Okayama, Japan
-
-
Aichi
-
Nagoyashi, Aichi, Japan
-
-
Ehime
-
Matsuyama, Ehime, Japan
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
-
-
Kumamoto
-
Goshi^shi, Kumamoto, Japan
-
-
Miyagi
-
Iwanuma-shi, Miyagi, Japan
-
-
Nagasaki
-
Omura, Nagasaki, Japan
-
-
Nara
-
Nara-shi, Nara, Japan
-
-
Niigata
-
Niigata-shi, Niigata, Japan
-
-
Oita
-
Yufu-shi, Oita, Japan
-
-
Osaka
-
Neyagawa-shi, Osaka, Japan
-
Osaka-shi, Osaka, Japan
-
Suita-shi, Osaka, Japan
-
-
Shiga
-
Moriyama-shi, Shiga, Japan
-
-
Shizuoka
-
Shizuoka-shi, Shizuoka, Japan
-
-
Tokyo
-
Kodaira, Tokyo, Japan
-
Kokubunji-shi, Tokyo, Japan
-
Shinjuku, Tokyo, Japan
-
-
Toyama
-
Toyoma-shi, Toyama, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 30 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Participants who have completed the evaluation of Week 12 of the E2080-J081-304 study.
- Male participants with reproductive ability and female participants with child-bearing potential, or their partners, had to be able to take medically appropriate contraceptive measures.
- Participants who have provided a written informed consent to participate in this clinical trial until the evaluation of week 12 of the E2080-J081-304 study.
- Participants who had a family member or a caregiver capable of recording the reporting diary, providing participant information necessary for the study, assisting treatment compliance, and accompanying the participant on scheduled visit days during the study period.
Exclusion criteria:
- Participants who were judged by the investigator that they are unfit to participate in this clinical study for safety reasons based on the information up to the evaluation of week 12 of the E2080-J081-304 Study.
- Participants who were judged by the investigator that they are likely to become non-compliant with administration during the clinical trial period.
- Participants who were judged by the investigator that they were unfit to participate in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Rufinamide
Ralfinamide was administered orally twice daily after breakfast and dinner.
Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period.
As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
|
The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide
Time Frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 years 10 months
|
Safety was assessed by monitoring and recording all adverse events (AEs), serious adverse events (SAEs), clinical laboratory tests, blood pressure, pulse rate, physical examination, and 12-lead electrocardiogram (ECG).
Treatment-emergent adverse events (TEAEs) were defined as AEs that started on or after the date and time of administration of first dose of test drug, but not later than 30 days after discontinuation from the study, or if the AE was present prior to the administration of the first dose of test drug and increased in National Cancer Institute Common Toxicity Criteria (NCI CTC version 3.0) grade during the study or 30 days after discontinuation from the study.
AEs were considered serious if it resulted in; death, was life-threatening, hospitalization/prolonged hospitalization, persistent or significant disability/incapacity, or a congenital anomaly/birth defect.
|
From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 years 10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)
Time Frame: Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
The sum of the frequencies of tonic seizures and atonic seizures was defined as the "tonic-atonic seizure frequency".
The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period in Study 304 as the baseline and the tonic-atonic seizure frequency at Weeks 12, 24, 32, 40, 52 and Week 52 Last Observation Carried Forward (LOCF) as the post-treatment value.
Percentage change in tonic - atonic seizure frequency was calculated as follows: [100 x (post-treatment value - baseline)/ baseline].
The frequency of epileptic seizures was recorded in the seizure diary by the recorder.
Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE).
The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.
|
Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percent Change in the Total Seizure Frequency From Baseline (Per 28 Days)
Time Frame: Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period of Study 304 as the baseline and the total seizure frequency per 28 days at Weeks 12, 24, 32, 40, 52 and Week 52 LOCF as the post-treatment value.
Percentage change in total seizure frequency was calculated as follows: [100 x (post-treatment value - baseline)/ baseline].
|
Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percent Change in the Frequency of Seizures Other Than Tonic-Atonic Seizures
Time Frame: Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Weeks, 12, 24, 32, 40, 52 and 52 LOCF as the post-treatment value.
Percentage change in total seizure frequency was calculated as follows: [100 x (post-treatment value - baseline)/ baseline].
Seizures analyzed other than tonic-atonic seizures included: Partial seizure frequency, Absence seizure, Atypical absence seizure, Myoclonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, and Unclassified epileptic seizure.
This data was based on the diary data collected for 7 days after each visit.
Seizure frequency was counted based on the classification established by the ILAE.
The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.
|
Baseline (Observation period in Study 304), Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percentage of Participants Who Achieved 100%, 75%, 50% or 25% Reduction in Tonic-Atonic Seizure Frequency (Responders)
Time Frame: Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Categorized percent change in Tonic-atonic seizure frequency per 28 Days by visit relative to the baseline (Observation Phase in Study 304) was determined based on the diary data collected for 7 days after each visit.
The Efficacy Analysis Set was used.
|
Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Percentage of Participants With An Increase In Tonic-Atonic Seizure Frequency
Time Frame: Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Number of participants with an increase in Tonic-atonic seizure frequency per 28 Days by visit relative to the baseline (Observation Phase in Study 304) was determined based on the diary data collected for 7 days after each visit.
The Efficacy Analysis Set was used.
|
Week 12, Week 24, Week 32, Week 40, Week 52 and Week 52 LOCF
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2010
Primary Completion (ACTUAL)
August 1, 2013
Study Completion (ACTUAL)
August 1, 2013
Study Registration Dates
First Submitted
June 14, 2010
First Submitted That Met QC Criteria
June 25, 2010
First Posted (ESTIMATE)
June 28, 2010
Study Record Updates
Last Update Posted (ACTUAL)
March 11, 2019
Last Update Submitted That Met QC Criteria
November 15, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epileptic Syndromes
- Genetic Diseases, Inborn
- Epilepsy
- Lennox Gastaut Syndrome
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Rufinamide
Other Study ID Numbers
- E2080-J081-305
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lennox-Gastaut Syndrome
-
Eisai Inc.TerminatedLennox-Gastaut Syndrome (LGS)Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
-
TakedaCompletedLennox Gastaut Syndrome (LGS)United States, China, Canada, France, Hungary, Australia, Poland, Spain, Japan, Belgium, Greece, Serbia, Germany, Italy, Latvia, Netherlands, Russian Federation, Ukraine
-
TakedaRecruitingLennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
-
University College, LondonKing's College London; King's College Hospital NHS Trust; University of Oxford; Great Ormond Street Hospital for Children NHS Foundation TrustRecruitingEpilepsy | Lennox-Gastaut Syndrome, IntractableUnited Kingdom
-
TakedaRecruitingDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Spain
-
NeuroPaceNational Institute of Neurological Disorders and Stroke (NINDS); University...RecruitingEpilepsy | Seizures | Lennox Gastaut Syndrome | Lennox-Gastaut Syndrome, Intractable | Seizures, GeneralizedUnited States
-
TakedaActive, not recruitingEpilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
-
GlaxoSmithKlineBausch Health Americas, Inc.Terminated
-
EpygenixNot yet recruiting
-
Eisai LimitedCompletedLennox-Gastaut SyndromeJapan
Clinical Trials on Rufinamide
-
Eisai LimitedCompletedLennox-Gastaut SyndromeJapan
-
Wuhan Union Hospital, ChinaCompleted
-
Eisai Inc.AvailableAn Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303Lennox Gastaut SyndromePoland
-
University of South AlabamaWithdrawnRefractory Partial SeizuresUnited States
-
Eisai Co., Ltd.CompletedLennox-Gastaut SyndromeJapan
-
Eisai Inc.CompletedLennox-Gastaut SyndromeFrance, Poland, United States, South Africa, Italy, Canada, Greece
-
Eisai Inc.TerminatedRefractory Partial Onset SeizuresUnited States
-
Biotie Therapies Inc.Syneos HealthCompletedGeneralized Anxiety DisorderUnited States
-
Eisai Inc.CompletedEpilepsyUnited States
-
University of ZurichWithdrawnPain | Peripheral Nerve InjuriesSwitzerland